Heart failure (HF) syndrome is a staggering public heath problem affecting an estimated 26 million patients worldwide. 1 This syndrome is responsible for more than 1 million hospitalisations annually on both sides of the Atlantic, and is the single most common cause of hospitalisation in patients older than 65 years. 1 Over the past 20 years, multiple pharmacological and device therapies have significantly improved outcomes in patients with HF and reduced ejection fraction. [2] [3] [4] However, the long-term prognosis of HF remains poor; the estimated 5 and 10-year survival rates following the diagnosis are as low as approximately 50% and approximately 10%, respectively. 2, 4 Hence, an early identification of HF patients at high risk of adverse outcomes is essential.
Given the complexity of HF, it is challenging to establish reliable risk stratification for adverse outcomes based only on clinical and routine laboratory findings. 5 To this end, demographic, clinical and laboratory variables have been combined into several prognostic scores for risk stratification in patients with acute and chronic HF (e.g. the heart failure survival score, Seattle heart failure model (SHFM), cardiac and comorbid conditions (3C-HF) score, PACE risk score, SHOCKED predictors, etc.). However, most risk scores have shown only modest ability for prognostic discrimination outside derivation cohorts, and their applicability in everyday clinical practice is uncertain. 6, 7 Biomarkers reflecting HF pathophysiology, such as B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NR-proBNP), are increasingly used for prognostication in HF. 8 In acute HF, increased BNP and NT-proBNP levels at admission are independent predictors of inhospital mortality, 9 while pre-discharge levels have a stronger association with post-discharge events. 10, 11 In chronic HF, elevated BNP or NT-proBNP levels parallel the severity of HF and indicate worse outcomes and higher mortality. [12] [13] [14] Likewise, changes in natriuretic peptide levels over time convey incremental prognostic value with respect to HF outcomes. 15 In the study published in the current issue of the European Journal of Preventive Cardiology, Arzilli et al. 16 have further advanced the concept of biomarker measurement in HF. They have assessed whether the addition of NT-proBNP to the two established risk scores improves stratification of the risk for all-cause and cardiovascular mortality in chronic HF patients. This was a retrospective analysis of 2023 patients with HF lasting 3 months or longer, left ventricular ejection fraction less than 50% and NT-proBNP levels determined in a clinically 'stable' setting. The 3C-HF risk score 17 was assessed in all patients. The more complex SHFM (SHFM score) 18 was determined in less than 40% of the participants. The primary and secondary study outcomes were all-cause and cardiovascular mortality at 1-year follow-up, respectively.
The authors followed recommended methodological steps for prognostic utility of biomarkers, including choosing a representative population and an adequate number of outcome events (i.e. 10% and 6% of allcause and cardiovascular deaths, respectively). 19 Also statistical analyses correctly included measures of discrimination, calibration and reclassification.
The study demonstrated that NT-proBNP provided similar discrimination of patients at risk of adverse outcomes as the two risk scores (i.e. the 3C-HF and SHFM). NT-proBNP also demonstrated good calibration for the outcomes. Compared with the 3C-HF score, NT-proBNP levels demonstrated better overall reclassification of the risk for all-cause death and improved net reclassification of cardiovascular mortality risk. There was no difference in reclassification ability between NT-proBNP levels and the SHFM score.
Importantly, the investigators tested the incremental value of NT-proBNP levels compared with the two reference risk scores. The addition of NT-proBNP to the 3C-HF score improved all metrics of prediction statistics for both outcomes. Considering the SHFM score, NT-proBNP had no incremental value in terms of discrimination, but provided an improvement in reclassification for all-cause and cardiovascular mortality. From the perspective of risk stratification, improvement in reclassification of patient's risk for an adverse outcome is considered more important than improvement in discrimination (i.e. the ability to distinguish between a binary event). 20 The present study is commendable in demonstrating that a single measurement of NT-proBNP can provide a refinement in risk stratification for 1-year mortality in stable HF patients on optimal medical treatment. 21 This finding underlies the fact that a modest improvement in prediction of all-cause and cardiovascular mortality could be achieved with inclusion of NT-proBNP into the established risk scores. 22 NT-proBNP testing is currently widely available and recommended by the 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic HF. 21 Nevertheless, there are several important limitations regarding the present study. First, this was a retrospective analysis based on a tertiary centre registry with a significant percentage of pertinent missing data. All participants had left ventricular ejection fraction less than 50%, and patients with HF with preserved ejection fraction were not included. 23, 24 Also, cut-off points of NT-proBNP used for the risk stratification were not reported. Finally, it is not known whether the improvement in reclassification was a result of down-classification of individuals without events or up-classification of patients with events.
Several studies have shown an improvement in prediction of HF-related outcomes after the addition of either BNP or NT-proBNP to a risk score. In patients with acute HF included in the ESCAPE trial, a score was developed to predict the risk of 6-month mortality and re-hospitalisation based on eight clinical variables and BNP. 25 Among the components of the score, BNP was the strongest predictor of mortality. The score provided a wide discrimination range for mortality between low-risk (i.e. 5% risk with the score of 0) and high-risk patients (i.e. 94% risk with the score 8-13). 25 In patients with acute HF, the predictive utility of NTproBNP was assessed with the advanced decompensated heart failure (ADHF)/NTproBNP risk score. This score assessed the incremental predictive value of NT-proBNP for 1-year all-cause mortality compared with a score containing six clinical variables. 26 Similar to the study reported by Arzilli et al., 16 the inclusion of NT-proBNP did not improve discrimination, but resulted in a significant improvement in reclassification for 1-year mortality risk. 26 Likewise, data from seven prospective studies were used to develop the ELAN-HF score for the prediction of 6-month allcause mortality risk in acute HF. 27 This score consisted of six clinical variables and incorporated NT-proBNP levels at discharge and the percentage change in NTproBNP levels during hospitalisation. The addition of NT-proBNP to a reference score resulted in a significant improvement of 62% in net reclassification for 6-month mortality risk. 27 In patients with chronic HF, a clinical risk score was developed in the GISSI-HF trial to estimate the longterm risk for all-cause mortality. 28 In a subset of patients with known high-sensitivity troponin and NTproBNP levels, these biomarkers were the most powerful predictors of the risk of death. The inclusion of troponin into a clinical risk score provided a significant improvement in reclassification. Although troponin and NT-proBNP were correlated, the addition of NTproBNP to the risk score with troponin had a small, but still evident, incremental reclassification value. 28 Other studies have shown that BNP and NTproBNP in combination with other biomarkers refine risk stratification when incorporated into 'multimarker' risk scores. 29, 30 The proposed explanation for the additive prognostic value of natriuretic peptides is that they indicate a residual risk that is not detectable with clinical and conventional laboratory parameters. Nevertheless, the prognostic value of BNP and NT-proBNP might be challenged with some novel biomarkers integrated into complex risk scores, 31 but their clinical utility awaits confirmation.
Whether the incremental predictive value of NTproBNP to the risk stratification in HF translates into improved survival is currently inconclusive. Biomarkerguided HF treatment was evaluated in several recent studies with conflicting results. In all trials, optimal medical treatment was compared with up-titration of medication doses targeting NT-proBNP levels below a certain threshold. In some trials, NT-proBNP-guided therapy reduced HF events, improved quality of life and demonstrated favourable effects on cardiac remodeling, particularly in patients 75 years of age or younger. [32] [33] [34] Conversely, other studies failed to show benefits with biomarker-guided management, 35, 36 including the recent GUIDE-IT study, which failed to show a reduction in HF hospitalisation or cardiovascular death with NT-proBNP-guided treatment compared with the standard of care. 37 A possible explanation for the negative result was that the majority of included patients had severe HF, which limited the ability to up-titrate medication doses to achieve target NTproBNP levels without the risk of adverse effects.
In conclusion, available evidence supports the utility of BNP and NT-proBNP in risk stratification of HF patients. The present study by Arzilli et al. 16 provides further insight into the role of biomarkers by demonstrating an additive value of NT-proBNP to the conventional risk scores. From the clinical perspective, improvement in the ability to 'flag' apparently stable chronic HF patients at high risk could benefit those patients. This benefit may come from providing close clinical follow-up, intensified treatment and earlier consideration of advanced treatment options. Conversely, low-risk chronic HF patients could be reassured about the prognosis and encouraged to adhere to the prescribed medications. The results of the present study encourage further research into a refinement in risk stratification in HF using biomarkers.
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